

The role of Prospective Strategies for a Possible Identification of Gadolinium Retention Issues

Sue-Jane Wang, OB/OTS/CDER/FDA



Conflict of Interest

No conflicts of interest reported.

The role of Prospective Strategies for a Possible Identification of Gadolinium Retention Issues



- Q: Can effect of gadolinium retention in brain be ruled out?
- Primary safety endpoint: neuropsychological battery: (Functional, Cognitive, Behavior)
- A pre-specified threshold challenging without clear signal
- Study population
 - Subjects requiring routine screening
 - At risk subjects (low vs high)
 - Diseased subjects (including, e.g., cancer with chemo)?
 - (Relatively) Healthy Volunteers (Q: taking questionnaires only or also receiving non-Gd enhanced MRI?)
- A prospective longitudinal cohort study with matched control a master protocol approach

Registration (enrollment) period – Master Protocol



FD

A Master Protocol Framework



- Multiple (8) GBCAs from 4 manufacturers
- Sharing of control arm across protocols
 - Concurrent control, external control or historical control
 - Imbalanced matching in settings with significant recruitment challenges
- Harmonized operational logistics, e.g., establish a trial network with infrastructure, streamlined enrollment process, and more
- Demographics, important baseline factors, potential confounders
- Model-based analysis methods for pooled analysis by body sites
 - If external control or historical control is used, can consider interim assessment of similarity between concurrent control and external control subjects



Sample Size Planning A Theoretical Exercise

- Assumptions
- Change from baseline
- Rate of change
- Scenarios, e.g., by type of matched-control